Leadership & Pay ·
Adicet Bio reported a net loss of $21.4 million for the quarter ended June 30, 2026, or $1.99 per share, with cash and…
ACETAdicet Bio, Inc.
Adicet Bio reported a net loss of $21.4 million for the quarter ended June 30, 2026, or $1.99 per share, with cash and short-term investments totaling $118.2 million. The company announced that Lloyd Klickstein has been appointed Interim Chief Medical Officer following the departure of Dr. Julie Maltzman. Clinically, Adicet plans to provide a comprehensive Phase 1 update for prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus in Q3 2026, featuring data from 22 patients with at least six months of follow-up. The company also anticipates initiating startup activities for a potential pivotal trial in the second half of 2026 following productive FDA interactions. Additionally, Adicet expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in Q3 2026, with Phase 1 enrollment anticipated in Q4 2026. Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.